US3645849A - Stability of enzymes - Google Patents
Stability of enzymes Download PDFInfo
- Publication number
- US3645849A US3645849A US817181A US3645849DA US3645849A US 3645849 A US3645849 A US 3645849A US 817181 A US817181 A US 817181A US 3645849D A US3645849D A US 3645849DA US 3645849 A US3645849 A US 3645849A
- Authority
- US
- United States
- Prior art keywords
- microwave energy
- exposure
- enzyme
- blood serum
- microwave
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/13—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultrasonic waves
Definitions
- Enzymes are generally unstable on standing in liquid aqueous medium whether in their natural menstruum (after removal from the living cell source) or after isolation from their natural menstruum and resuspension or redissolution (reconstitution) in a prepared aqueous medium.
- the foregoing exemplifies problems encountered through instability of enzyme preparations, and has been discussed at length since blood serum represents a particularly delicate and unstable enzyme-containing material to which the present invention is particularly applicable.
- the present invention is applicable to enzymes in general, whether in their natural menstruum (after removal from their natural living cell source or environment) or reconstituted.
- the method of the present invention comprises cooling an enzyme in aqueous medium to below 50 F and, in quick succession, (a) subjecting the enzyme in a treating zone, while held in a closed, microwave-permeable container within said treating zone, to microwave energy through a moving atmosphere of coolant gas, for a period of time short of inactivation of the enzyme, said moving atmosphere being in direct contact with microwave-permeable walls of said container but out of direct contact with said enzyme and being at a temperature below 60 F. upon its admission to said treating zone, (b) discontinuing exposure of said enzyme to said microwave energy at the end of said period, and (c) cooling said enzyme.
- the circulation of coolant gas is continued, after discontinuance exposure of the enzyme to the microwave energy, for a period to provide at least a portion of the stated cooling.
- the enzyme material is cooled to below 50 F., and at least the latter portion of this cooling may be achieved by other means, as by contacting a container of said enzyme material with a cold liquid, like cold water.
- the container of enzyme-material be rotated during the exposure to the microwave energy at a rate to provide at least one complete rotation of 360 during said exposure, and preferably a plurality of 360 rotations, to insure presentation of all major walls of the container to the microwave energy during the stated exposure.
- the foregoing treatment is capable of markedly enhancing the stability of the treated enzymes against deterioration, that is, against permanent loss of activity. It is known that enzymes can become deactivated, even permanently, by more drastic thermal treatments, including exposure to microwave energy.
- the treatment of the present invention through the effects of precooling and rapid postcooling, in combination with the effects of the coolant gas during exposure to microwave radiation and the limited extent of the latter, prevents deactivation of the enzyme while at the same time enhancing the stability of the enzyme. This is illustrated in the examples set forth hereinafter, and especially so in the example dealing with blood serum.
- Stabilization according to the present invention is accomplished rapidlyin a matter of seconds-as well as simply and economically.
- Conditions can be standardized for any particular enzyme or mixture of enzymes to provide reproducible results from time to time.
- each lot or batch can be assayed by techniques specific for each enzyme.
- Enzymes are proteins, including metaloproteins and conjugated proteins, and are produced by living cells. Although there are various classifications of enzymes, one accepted classification is according to Webb, Biochemical Engineering, D. Van Nostrand Co., lnc., Princeton, N.J., 1964 (see also Encyclopedia of Chemical Technology. Kirk-Othmar, Second Ed., Vol.
- enzymes-proteases and peptidases such as pepsin, rennin, and the like; carbohydrases, such as amylases; esterases, such as lipases, phosphatases, and the like; urease; deaminase; etc.; (2) transferring enzymes-dehydrogenases, like lactic dehydrogenase; oxidases; transaminases, like glumatic transaminases; kinases, like creatine phosphokinase; (3) addition and subtraction enzymes-like aconitase, enolase, carboxylase and aldolase; (4) isomerases-like alanine racemase; (5) synthetaseslike glutamine synthetase; and (6) nucleases-like deoxyribonuclease.
- enzymes-proteases and peptidases such as pepsin, rennin, and the like
- carbohydrases such as am
- the present invention is particularly applicable to the treatment of enzymes in blood serum which include phosphatases, transaminases, dehydrogenases and phosphokinase. Any one or all of these may be isolated from blood serum and treated separately, after reconstitution, if necessary, or blood serum as such may be treated.
- Blood serum which is the clear liquid remaining after removing cellular elements (red and white cells and platelets) and the coagulating mechanism (fibrinogen) from whole blood, is one of the particularly preferred materials treated in accordance with the present invention.
- the enzyme treated in accordance with the present invention will be in an aqueous mediumthat is, it will not be dry. It may be in its natural menstruum with or without concentration or it may be reconstituted by suspension or dissolution in a prepared aqueous medium after isolation from or concentration in its natural menstruum.
- the amount of aqueous medium associated with the enzyme is not critical, so long as sufficient is present to wet the enzyme, and may well be dictated by the ultimate use for the product or handling considerations. For example, it is often most convenient to work with a liquid suspension or solution.
- microwave energy is the electromagnetic wave energy of the wave length falling in the microwave region of the electromagnetic spectrum.
- the Federal Communications Commission has presently set aside, for microwave processing, bands of microwave energy within the range of between about 400 and about 20,000 megacycles per second, with a wave length ranging from about 13 inches for the lower frequencies to about 0.7 inch for the highest frequencies; specifically frequencies of about 890-940 with a wavelength of about 13 inches; frequencies of about 2,400-2,500 with a wavelength of about 4-5 inches, and frequencies of 17,850-1 8,000 with a wavelength of about 0.7 inch.
- bands of microwave energy within the range of between about 400 and about 20,000 megacycles per second, with a wave length ranging from about 13 inches for the lower frequencies to about 0.7 inch for the highest frequencies; specifically frequencies of about 890-940 with a wavelength of about 13 inches; frequencies of about 2,400-2,500 with a wavelength of about 4-5 inches, and frequencies of 17,850-1 8,000 with a wavelength of about 0.7 inch.
- the presently preferred microwave energy for use according to the present invention is an intermediate range having a frequency of from about 1,000 to about 5,000, and more particularly from about 2,000 to about 3,000, megacycles per second.
- Microwave energy is generated from a suitable high frequency source, such as a magnetron.
- One feature of the present invention is the precooling of the enzyme material.
- the material at the time it is first exposed to the microwave energy should be well below room temperature, that is below about 50 F. While it may actually be frozen, since it will thaw upon exposure to the microwave energy, there is no need for this and, for ease of handling, it is preferably at a temperature above freezing. A temperature in the range of from about 35 to about 45 F. is particularly satisfactory.
- the enzyme material may be precooled outside the treating chamber or zone or it may be precooled within the treating chamber or zone by preliminary flow of the coolant gas before generation of the microwave energy.
- Another feature of the present invention is holding the enzyme material being treated in a sealed container during the treatment.
- the walls of the container may be conventional, substantially gas-impermeable packaging materials like glass, polymethylmethacrylate, polystyrene and polyethylene, as in bottles, flasks, and pouches.
- the container will be essentially gas tight.
- the container holding the enzyme material during exposure will be held in a larger treating chamber or zone into which the microwave energy is directed to penetrate the microwaveperrneable wall of the container and permeate the enzyme.
- Still another feature of the invention is. the circulation of a coolant gas through the treating chamber or zone and around the walls of the container holding the enzyme material.
- the coolant gas employed may be any substantially inert (nonreactive with the environment in the presence of microwave energy) gas existing as a gas at the temperatures employed, especially air, nitrogen or carbon dioxide. While gases like argon, helium, neon, krypton, xenon, ethylene oxide, and mixtures thereof, and the like, are equivalent, they are less desirable at the present because of their cost.
- the temperature of the coolant gas entering the treating zone should be below about 60 F., and is preferably below about 55 F. While the temperature thereof may go as low as F., there is no advantage in it going below about 20 F. and at such lower temperatures there may be freezing problems if an enzyme material is left in the treating zone containing the cold gas for extended periods after the source of microwave energy has been turned off.
- a temperature for the incoming gas between about 30 and about 50 F. has been found to be particularly suitable.
- the coolant gas will become warmed during its travel through the treating zone, particularly from contact with the walls of the container holding the enzyme material, and the warmed gas is removed from the treating zone making way for incoming coolant gas. When the gas is recirculated for reuse, the temperature thereof must be reduced back to the desired temperature for admission to the treating zone.
- the coolant gas Since the principal function of the coolant gas is to keep the walls of the container at a temperature well below that of the enzyme material being treated, forcing the coolant gas into the treating chamber and past the walls of the container under at least some positive pressure (at least slightly above atmospheric pressure) provides more efficient overall cooling without some area or areas of the walls becoming insufficiently cooled. Pressures as low as 0.03 p.s.i.g. have been used and pressures as high as 50 p.s.i.g. may be desirable. Air is particularly satisfactory at low positive pressures, whereas a substantially oxygen-free gas, especially nitrogen, is preferred at higher pressures.
- the precise time of treatment with microwave energy according to the present invention may depend somewhat upon the particular enzyme being treated, the volume of the enzyme material, the concentration of enzyme in the material being treated and the power of the microwave-generating means. In general, the time required is directly proportional to the volume of enzyme-containing material and concentration of enzyme therein and is inversely proportional to the power of the microwave-generating means. It has been found that the exposure time, in any case, will be at least about one second. It has also been found that overexposure results in complete inactivation of the enzyme. Since this is undesirable in accordance with the present invention the total exposure time will be short of that producing such complete inactivation.
- each enzyme has its own assay so that it can readily be determined whether or not a treated sample thereof has become completely inactivated. ln any event, the time is short of that causing the temperature rise in the enzyme material to the temperature of permanent inactivation of the enzyme; generally the time is not longer than that causing a temperature rise in the enzyme material above about l25l 30 F., and in most cases the temperature rises to from about to about F.
- the enzyme material may be subjected, according to the present invention, to a single exposure or to a plurality of exposures to the microwave energy.
- a feature of the preferred process of the present invention is the presentation of all the major walls of the container holding the enzyme material directly to the microwave energy during the stated exposure. This is most conveniently done, using an upright bottle as the container, by rotating the bottle about its longitudinal (vertical) axis at least once (360), and preferably a plurality of times, during exposure of the bottle to the microwave energy directed toward the bottle in a generally horizontal direction, i.e., in a direction generally normal to the major walls of the container. This presents all major side walls of the container, whether it be circular, square, rectangular or polygonal in cross section, directly to the microwave radiation.
- microwave energy After exposure to the microwave energy for the required period of time, exposure to microwave energy is discontinued and the enzyme material is quickly cooled. It is preferred, in this regard, to continue the cooling effect of the coolant gas after exposure to the microwave energy has been discontinued in order to cool or chill the treated enzyme material, preferably down at least to about 85 F. This can be accomplished by leaving the container of enzyme material in the treating zone, through which is circulated the coolant gas, after the source of microwave energy has been turned off, or, in the case of a continuously moving line of containers of enzyme material, by extending the movement beyond the field of direct microwave exposure while continuing the flow of coolant gas in contact with the containers.
- the enzyme material may be cooled by other means, supplemental to or instead of, the foregoing means, as by contacting the walls of the container with a cold liquid, like cold water, or by placing the container in a refrigerator. In any event, it is preferable to cool the treated enzyme material to below 50 F.
- Lactic dehydrogenase was dissolved in a phosphate-buttered aqueous nonserum base (pH about 7.2) to provide 627 units/mL, and the solution was filtered through a bacterial filter.
- Small sterile glass bottles (7 ml. nominal capacity) were filled with the solution, capped and the bottles were cooled to 40 F. Forty-eight of the bottles were then placed in a pressure chamber equipped with a 2-kw. magnetron connected to a 220-volt source of alternating current and capable of delivering microwave energy into the chamber at about 2,450 megacycles per second. The bottles were divided into groups of three, and each group was held on a small individual turntable.
- the turntable assembly was made of polymethylmethacrylate. Cold nitrogen gas was flowed into, through and out of the chamber, at a pressure of 2.5 p.s.i.g., its inlet temperature being about 35 F. The magnetron was next turned on for 62 seconds, the magnetron and associated wave guide being positioned to direct the microwave energy in a horizontal direction toward the side walls of the bottles. The maximum temperature reached by the solution was about 120 F.
- treated material 40 F.after 13 days, 583 units/mL; after 20 days, 375 units/ml. 70 F.after 13 days, 497 units/ml.; after 20 days, 375 units/ml. 100 F.after 13 days, 520 units/mL; after 20 days, 400 units/ml. control: 1 40 F.after 1 week, 315 units/ml; after 13 days, 0. 70 F. after 1 week, F.after 100 F.after 48 hours, 0.
- Serum glutamic oxalacetic transaminase was dissolved in a phosphate-buffered aqueous nonserum base (pH about 7.2) to provide 37 units/mL, and filtered through a bacterial filter.
- the solution was bottled, treated, stored and assayed as in Example 1 with the following results: treated material: 40 F.after 13 days, 26.7 units/ml. after 20 days, 20 units/ml. 70 F.after 13 days, 13 units/ml; after 20 days, 10 units/ml. 100 F.after 13 days, 16 units/ml; after 20 days, 3 units/ml. control: 40 F.after 1 week, 0. 70 F.after 4 days, 0. 100 F.-after 48 hours, 0.
- EXAMPLE 3 Five milligrams of deoxyribonuclease, from bovine pancreas, were reconstituted with 1 ml. of distilled water and then diluted to 800 ml. with distilled water. The solution was filtered through a bacterial filter. The starting potency after filtration was 786 units/mg. Small sterile glass bottles (7 ml. nominal capacity) were filled with the solution, capped and cooled to 40 F. Various samples (24 bottles per lot) were then treated as in Example 1 but for different exposure times as follows:
- a 415 8 520 C 450 Control 200 Averages of two bottles from each treatment, three separate samples from each bottle.
- EXAMPLE 4 Liver fraction lactic dehydrogenase isoenzyme, extracted from bovine heart, was dissolved in sterile distilled water to l unit/mL, and the solution was filtered through a bacterial filter. Small sterile, glass bottles (7 ml. nominal capacity) were filled with the solution, capped and cooled to 40 F. Fortyeight of the bottles were then exposed to microwave energy in the presence of cold flowing nitrogen gas as in Example 1 but for an exposure time of 56 seconds. After removal from the chamber at a temperature of about 80 F., and cooling to 40 F., the treated samples, along with untreated controls, were stored at room temperature. The controls became completely inactive on standing overnight, whereas the treated material was as active as the original after standing for three weeks. At the end of three months, there was less than 10 percent loss in activity in the treated material.
- EXAMPLE 5 Heart fraction lactic dehydrogenase isoenzyme, extracted from rabbit muscle, was dissolved in sterile distilled water to l unit/ml, and the solution was filtered through a bacterial filter. After bottling and capping, the material was treated and then stored as in Example 4. The controls became completely inactive on standing overnight, whereas the treated material was as active as the original after standing for three weeks. At the end of three months, there was less than 10 percent loss in activity in the treated materials.
- EXAMPLE 6 An aqueous solution of amylase (1,000 units/ml.) was I prepared and filtered through a bacterial filter, and 10 ml. portions thereof were placed in six small sterile glass bottles (10 ml. nominal capacity) which were then capped. The six bottles were then cooled to 40 F., and three of them were placed in a pressure chamber equipped with a 2-kw. magnetron connected to a 220-volt source of alternating current and capable of delivering microwave energy into the chamber at about 2,450 megacycles per second. Each bottle was held on a small individual turntable, each of which was held on a larger turntable, so while the large turntable was rotating the small individual turntables, and the bottles thereon, were also rotating.
- the turntable assembly was made of polymethylmethacrylate.
- the large turntable and the small individual turntables were rotated at 30 r.m.p.
- Cold nitrogen gas was then flowed into, through and out of the chamber, at a pressure in the chamber of 2.5 p.s.i.g., its inlet temperature being about 35 F.
- the magnetron was next turned on for 7 seconds, the magnetron and associated waveguide being positioned to direct the microwave energy in a horizontal direction toward the side walls of the bottles. After the magnetron was turned 800 units/ml. ZOOunits/ml.
- the method of improving the stability of an enzyme which comprises cooling an enzyme in aqueous medium to below 50 F and then in quick succession, (a) subjecting the enzyme in a treating zone, while held in a closed, microwave- TABLE 1 4 aiues alter designated days Constituent days days days days days Upper limit- 145 143 142 142. 5 142 Sodium Mea 41. 8 140. 8 140. 9 141 141. 5
- LDH fractionation isoenzymes liver fraction (LDH!) Mean 22.5 21. 5 21. 3 21. 4 21. 2
- Creatine phosphokinase (C.P.K.) Mean 5. 3 5. 4 5. 0
- SGOT serum glutamjc oxalacetic transaminase
- SGPT serum glutamic pyruvic transaminase
- LDH lactic dehydrogenase
- the treated material showed normal electrophoresis throughout the testing period.
- microwave energy having a frequency between about 400 and about 20,000 megacycles per second
- a moving atmosphere of coolant gas for a period of at least 1 second but short of inactivation of the enzyme and of causing a temperature rise in the enzyme material above about 130 F., said moving atmosphere being in direct contact with microwave-permeable walls of said container but out of direct contact with said enzyme and being at a temperature below about 60 F., upon its admission to said treating zone; (b) discontinuing exposure of said enzyme to said microwave energy at the end of said period and (c) cooling said enzyme.
- microwave energy has a frequency of from about 1,000 to about 5,000 megacycles per second.
- microwave energy has a frequency of from about 2,400 to about 2,500 megacycles per second.
- microwave energy has a frequency of from about 2,000 to about 3,000 megacycles per second.
- the microwave energy has a frequency of from about 2,000 to about 3,000 megacycles per secondj wherein the blood serum does not exceed a v temperature of about F. during said exposure to said microwave energy; and wherein, after discontinuing the exposure of said blood serum to said microwave energy, said blood serum is cooled to below about 50 F.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81718169A | 1969-04-17 | 1969-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3645849A true US3645849A (en) | 1972-02-29 |
Family
ID=25222518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US817181A Expired - Lifetime US3645849A (en) | 1969-04-17 | 1969-04-17 | Stability of enzymes |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3645849A (fr) |
| AT (1) | AT295453B (fr) |
| AU (1) | AU1362570A (fr) |
| BE (1) | BE749082A (fr) |
| CA (1) | CA920524A (fr) |
| CH (1) | CH525914A (fr) |
| DE (1) | DE2017571C3 (fr) |
| ES (1) | ES378692A1 (fr) |
| FR (1) | FR2039250A1 (fr) |
| GB (1) | GB1267475A (fr) |
| IL (1) | IL34291A (fr) |
| NL (1) | NL7005554A (fr) |
| SE (1) | SE355817B (fr) |
| TR (1) | TR16728A (fr) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250139A (en) * | 1979-02-01 | 1981-02-10 | Collagen Corporation | Microwave sterilization of dry protein |
| US4994237A (en) * | 1987-10-02 | 1991-02-19 | The Beth Israel Hospital Association | Microwave preservation of bioprostheses |
| US5283034A (en) * | 1989-06-29 | 1994-02-01 | Applied Immune Sciences, Inc. | Stabilization of sterilized surfaces for research and medical use |
| US5372149A (en) * | 1992-03-25 | 1994-12-13 | Roth; David S. | Sterilization process in the manufacturing of snuff |
| US5534026A (en) * | 1992-04-02 | 1996-07-09 | The Penn State Research Foundation | Preparation of inexpensive, HIV-free human skin allograft |
| US5730933A (en) * | 1996-04-16 | 1998-03-24 | Depuy Orthopaedics, Inc. | Radiation sterilization of biologically active compounds |
| US6114680A (en) * | 1996-01-17 | 2000-09-05 | Perkin Elmer Llc | Method for processing a sample |
| US6143508A (en) * | 1989-06-29 | 2000-11-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| US6432653B1 (en) | 1989-06-29 | 2002-08-13 | Aventis Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| US20090186332A1 (en) * | 2006-03-15 | 2009-07-23 | Manders Ernest K | Preparation and storage of stable, antimicrobially active materials |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL58541A (en) * | 1978-11-01 | 1982-02-28 | Nordisk Insulinlab | Antihemophilic factor preparation from human blood plasma and a process for producing it |
| NL1005028C2 (nl) * | 1997-01-17 | 1998-07-20 | Franciscus Matheus Everaerts | Werkwijze voor het controleren van een enzymreactie. |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2683682A (en) * | 1950-02-06 | 1954-07-13 | Research Corp | Differential inactivation of enzymes |
| US3006815A (en) * | 1956-08-24 | 1961-10-31 | Fermco Lab Inc | Heat stabilization of enzymes and method |
| US3284301A (en) * | 1963-08-28 | 1966-11-08 | American Cyanamid Co | Plasmin sterilization |
| US3494723A (en) * | 1967-12-05 | 1970-02-10 | Gray Ind Inc | Method and apparatus for controlling microorganisms and enzymes |
-
1969
- 1969-04-17 US US817181A patent/US3645849A/en not_active Expired - Lifetime
-
1970
- 1970-04-07 CA CA079426A patent/CA920524A/en not_active Expired
- 1970-04-08 GB GB06770/70A patent/GB1267475A/en not_active Expired
- 1970-04-08 AU AU13625/70A patent/AU1362570A/en not_active Expired
- 1970-04-09 IL IL34291A patent/IL34291A/en unknown
- 1970-04-13 DE DE2017571A patent/DE2017571C3/de not_active Expired
- 1970-04-14 CH CH552770A patent/CH525914A/fr not_active IP Right Cessation
- 1970-04-15 SE SE05151/70A patent/SE355817B/xx unknown
- 1970-04-16 ES ES378692A patent/ES378692A1/es not_active Expired
- 1970-04-17 NL NL7005554A patent/NL7005554A/xx unknown
- 1970-04-17 TR TR16728A patent/TR16728A/xx unknown
- 1970-04-17 FR FR7014063A patent/FR2039250A1/fr not_active Withdrawn
- 1970-04-17 AT AT351170A patent/AT295453B/de not_active IP Right Cessation
- 1970-04-17 BE BE749082D patent/BE749082A/fr unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2683682A (en) * | 1950-02-06 | 1954-07-13 | Research Corp | Differential inactivation of enzymes |
| US3006815A (en) * | 1956-08-24 | 1961-10-31 | Fermco Lab Inc | Heat stabilization of enzymes and method |
| US3284301A (en) * | 1963-08-28 | 1966-11-08 | American Cyanamid Co | Plasmin sterilization |
| US3494723A (en) * | 1967-12-05 | 1970-02-10 | Gray Ind Inc | Method and apparatus for controlling microorganisms and enzymes |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250139A (en) * | 1979-02-01 | 1981-02-10 | Collagen Corporation | Microwave sterilization of dry protein |
| US4994237A (en) * | 1987-10-02 | 1991-02-19 | The Beth Israel Hospital Association | Microwave preservation of bioprostheses |
| US5283034A (en) * | 1989-06-29 | 1994-02-01 | Applied Immune Sciences, Inc. | Stabilization of sterilized surfaces for research and medical use |
| US6143508A (en) * | 1989-06-29 | 2000-11-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| US6432653B1 (en) | 1989-06-29 | 2002-08-13 | Aventis Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| US5372149A (en) * | 1992-03-25 | 1994-12-13 | Roth; David S. | Sterilization process in the manufacturing of snuff |
| US5534026A (en) * | 1992-04-02 | 1996-07-09 | The Penn State Research Foundation | Preparation of inexpensive, HIV-free human skin allograft |
| US6114680A (en) * | 1996-01-17 | 2000-09-05 | Perkin Elmer Llc | Method for processing a sample |
| US5730933A (en) * | 1996-04-16 | 1998-03-24 | Depuy Orthopaedics, Inc. | Radiation sterilization of biologically active compounds |
| US20090186332A1 (en) * | 2006-03-15 | 2009-07-23 | Manders Ernest K | Preparation and storage of stable, antimicrobially active materials |
Also Published As
| Publication number | Publication date |
|---|---|
| CH525914A (fr) | 1972-07-31 |
| DE2017571C3 (de) | 1973-10-04 |
| FR2039250A1 (fr) | 1971-01-15 |
| IL34291A (en) | 1973-03-30 |
| NL7005554A (fr) | 1970-10-20 |
| DE2017571B2 (de) | 1973-03-01 |
| BE749082A (fr) | 1970-10-19 |
| TR16728A (tr) | 1973-03-01 |
| IL34291A0 (en) | 1970-06-17 |
| AT295453B (de) | 1972-01-10 |
| AU1362570A (en) | 1971-10-14 |
| DE2017571A1 (fr) | 1970-10-29 |
| GB1267475A (en) | 1972-03-22 |
| SE355817B (fr) | 1973-05-07 |
| CA920524A (en) | 1973-02-06 |
| ES378692A1 (es) | 1972-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3645849A (en) | Stability of enzymes | |
| EP0182579B1 (fr) | Méthode de stabilisation d'une enzyme immobilisée fibrinolytique | |
| US4687664A (en) | Method of inactivating reproducible pathogens | |
| DE69922362D1 (de) | Methode zur präparation eines diafiltrierten stabilen blutproduktes | |
| US20030068416A1 (en) | Method of lyophylization to reduce solvent content and enhance product recovery | |
| Hugo | The preparation of cell-free enzymes from microorganisms | |
| US20040126880A1 (en) | Sterilization, stabilization and preservation of functional biologics | |
| Hegeman | [89] Benzoylformate decarboxylase (Pseudomonas putida) | |
| WO1983004027A1 (fr) | Stabilisation thermique des proteines du plasma | |
| Eisen et al. | Plasma kininogenases and their activators | |
| US4579735A (en) | Process for the pasteurization of human residual plasma | |
| US2705696A (en) | Production of antigens | |
| US20080220492A1 (en) | Stabilization of biological materials through inactivation of metalloenzymes | |
| Kennedy et al. | Papain, chymotrypsin and related proteins—a comparative study of their beer chill-proofing abilities and characteristics | |
| JPS61501510A (ja) | ビ−ルスリスクを減らしたヘモグロビンおよびその製造方法 | |
| AU2007205748B2 (en) | Sterilization, stabilization and preservation of functional biologics | |
| CN101759766B (zh) | 一种动物源可凝固蛋白的制备方法 | |
| Garner et al. | Effect of storage at 5 C on the disc electrophoretic patterns of ovine and bovine seminal proteins | |
| CN121896186A (zh) | 一种高稳定性超氧化物歧化酶的制备方法 | |
| JPS6354681B2 (fr) | ||
| Glew | Some effects of ionizing radiations on liquid whole milk and whey protein | |
| Barnhart | Generation of prothrombin activity with mitochondria or with cathepsin | |
| RU2061755C1 (ru) | СПОСОБ СТАБИЛИЗАЦИИ УЛЬТРАКОНЦЕНТРАТА ГРИБНОЙ β -ГАЛАКТОЗИДАЗЫ | |
| JPS5726625A (en) | Sustained release type composite material entrapping medical enzyme and its preparation | |
| Polakoski et al. | Studies on the purification and characterization of boar acrosin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ETC, LTD., A FL. LIMITED PARTNERSHIP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:GRAY, OSCAR S.;REEL/FRAME:003862/0016 Effective date: 19810518 |
|
| AS | Assignment |
Owner name: GRAY, GREGORY PERSONAL REPRESENTATIVE OF THE ESTAT Free format text: ORDER FILED IN THE CIRCUIT COURT OF BROWARD COUNTY, FLORIDA;ASSIGNOR:ETC. LTD., AFL PARTNERSHIP;REEL/FRAME:005079/0790 Effective date: 19890713 |